Vir Biotechnology Inc (VIR) NPV
Vir Biotechnology, Inc. is a clinical-stage immunology company focused on treating and preventing serious infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid (siRNA), through internal development, collaborations, and acquisitions. Its development pipeline consists of product candidates targeting the coronavirus disease 2019 (COVID-19), hepatitis B virus (HBV), influenza A virus and human immunodeficiency virus (HIV). Its product candidates include VIR-7831 and VIR-7832, VIR-2218, VIR-3434, VIR-2482 and VIR-111. The Company is developing VIR-7831 and VIR-7832 for the treatment of COVID-19 infection, which are severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing monoclonal antibody (mAbs). VIR-2218 and VIR-3434, are for the treatment of HBV. VIR-2482 is an intramuscularly administered influenza A-neutralizing mAb.VIR-1111 is a subcutaneously administered HIV T cell vaccine.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.